Company intelligence / Profile preview

Acanthas Pharma, Inc.

Montréal, Quebec, Canadainformaconnect.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company's lead drug candidate STAR-101 was in clinical development but has been discontinued. A Phase 1 clinical trial (NCT04081597) for evaluating the safety, tolerability, and pharmacokinetic properties of STAR-101 was withdrawn[4].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

ESP-01

Phase 2

Indications: High-grade serous ovarian cancer, Pancreatic cancer, Ewing sarcoma

3 more assets in the full pipeline.

Request access →

Partnerships

TVM Capital Life Science

Beyond the preview

Go deeper on Acanthas Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acanthas Pharma, Inc..

Explore the full profile